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ABSTRACT 
Background: Malignant mesothelioma is an aggressive cancer with no effective treatment 
options. Of phytochemicals, tocotrienol (T3), a member of vitamin E, is one of the most 
potent anti-mesothelioma agents, but the effectiveness in vivo is quite limited, due to its low 
bioavailability. In this study, we investigated if the oral treatment of -T3 inclusion with 
-cyclodextrin (CD) could improve the bioavailability and anticancer activity of the T3.   
 
Findings: Using nude mice bearing MSTO-211H cells (a human malignant mesothelioma 
cell line), the effect of -T3 inclusion with -CD on -T3 level in tumor tissues, tumor growth, 
and its related mRNA levels were examined. The difference of tumor growth between the two 
groups had no statistical significance, but the latter showed a lower tendency compared with 
the former. In linked with this observation, the level of vascular endothelial growth factor 
mRNA required for in vivo tumor growth in -T3 inclusion with -CD group was lower than 
that in -T3 group, on the contrary, the level of -T3 level showed an opposite tendency. 
 
Conclusion: Our study demonstrated that the bioavailability of -T3 was improved by an oral 
administration of a novel -T3 inclusion complex with CD. Furthermore, the improvement of Functional Foods in Health and Disease 2011, 1(12):508-515                                                   Page 509 of 515 
 
 
the bioavailability contributed to the increase of anticancer activity of -T3 in vivo.   
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FINDINGS: Malignant mesothelioma from the serosal membranes of the body cavities is a 
particularly aggressive cancer, which is characterized by rapid progression, late metastases, 
and  poor  prognosis  [1].  Although  surgery,  radiotherapy,  chemotherapy,  and/or  their 
combinations  have  been  used  as  therapeutic  modalities,  median  patient  survival  is  8–18 
months  [2].  Malignant  mesothelioma  cells  exhibit  resistance  to  many  chemotherapeutic 
agents,  including doxorubicin and cisplatin, which are, nevertheless, widely used to  treat 
Malignant  mesothelioma  [3].  A  recent  report  of  a  phase  III  study  showed  that  the 
combination  of  pemetrexed  and  cisplatin  is  more  effective  than  cisplatin  alone,  with 
differences in response rates of 41.3%, versus 16.3% [4]. However, most of the patients 
relapsed within a year after starting the treatment. Therefore, new therapeutic approaches are 
urgently needed for malignant mesothelioma patients. 
Vitamin E is one of the most promising lipophilic antioxidants, consisting of eight 
naturally  occurring forms, known as  tocopherols (Ts), and tocotrienols  (T3s). Ts carry  a 
saturated phytyl  group that is derived from homogentisic acid and phytyl pyrophosphate, 
whereas  T3s  are  thought  to  arise  from  the  condensation  of  homogentisic  acid  and 
geranylgeranyl pyrophosphate [5]. Ts and T3s can be subdivided into four isomers ( 
and ʴ) relating to the numbers and the position of the methyl groups on their chromanol ring. 
The major source of vitamin E is plant-derived oils. T3s are the major vitamin E component 
of palm oil. Significant amounts are also found in barley, oats, and rice bran [6,7]. Since T3s 
differ from Ts by the presence of three trans double bonds in the hydrocarbon tail, T3s are 
thought  to  assume  a  unique  conformation.  Therefore,  members  of  the  natural  vitamin  E 
family  possess  overlapping  and  unique  functional  properties  that  could  be  due  to  their 
structural difference. Among these, T3s, but not Ts, have been linked to additional beneficial 
therapeutic properties, such as lowering serum cholesterol levels when administered in the 
diet  of  hypercholesterolemic  humans  [8].  Moreover,  recent  studies  also  revealed  their 
beneficial  biological  properties,  such  as  anti-angiogenesis,  and  anticancer  activities  [9]. 
Therefore, T3s are one of the attractive groups, not only as a functional food constituent but 
also as a clinical therapeutic agent. Especially, -T3 is the most potent anti-cancer isoforms of 
T3 isforms, so this isform is as promising as a clinical therapeutic agent.     
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D-glucose units. The -CD, -CD and -CD are widely used natural CDs. The D-glucose 
units are covalently linked at the carbon atoms C1 and C4 to form a macrocycle [10,11]. CDs 
can generally form inclusion complexes with a number of lipophilic substances, and thus 
have been used for improving their water solubility, stability, diffusibility, and bioavailability 
[12,13]. Previous studies have shown that the bioavailability of coenzyme Q10 was improved 
by CD inclusion [14]. Among the three natural CDs, -CD shows the highest water solubility 
and is the only form digested in the intestinal tract. Therefore, much attention has recently 
been  given to  the usage of  -CD as a  ―host‖  molecule of the inclusion complex in  oral 
bioavailability experiments and as a promising nutrition delivery system.   
The aim of this study was to examine the effect of -T3 inclusion with -CD on its 
bioavailability. Further, we evaluated anti-mesothelioma activity of this inclusion. A T3-rich 
fraction (TRF) was prepared by extraction from rice bran, which is a readily available and 
abundant source of γ-T3. 
 
METHODS: 
A TRF or a TRF inclusion complex with -CD (TRF/CD). TRF (Oryza tocotrienol 72), -CD, 
and TRF/CD were provided by Oryza Oil & Fat Chemical Company (Aichi, Japan), and 
Cyclochem (Kobe, Japan). TRF contained vitamin E as follows: 0.5% ʱ-T, 0.4% β-T, 2.8% 
-T, 0.5% ʴ-T, 1.8% ʱ-T, 0.4% β-T, 65.0% -T3 and 4.6% ʴ-T3. All animal experiments 
were approved by the local animal ethics committee and performed according to guidelines 
for the care and use of laboratory animals at the University. Small fragments of tumor (2 × 2 
× 2 mm) established from MSTO-211H cells (a human malignant mesothelioma cell line) 
were  transplanted  subcutaneously  into  the  right  flank  region  of  4  to  5-week-old  female 
athymic CAnN.Cg-Foxn1
nu/CrlCrlj mice (Charles River Laboratories Japan Inc., Yokohama, 
Japan). After 3 days, the mice received oral treatment of TRF, TRF/CD or CD (control), three 
times a week for 4 consecutive weeks. The mice were weighed and the tumor was measured 
every 3 or 4 days. Tumor volume was calculated as (π/6) ￗ large diameter ￗ (small diameter)
2. 
On day 33, tumors were carefully removed after death, and stocked at −80 °C for isolation of 
RNA or T3 analysis. The following equivalent doses of TRF and -CD were used for oral 
administration on Days 28, 30 and 32: TRF, 2.79 mg in 200 μl of corn oil; TRF/CD, 14.5 mg 
in 200 μl of corn oil; -CD, 11.71 mg in 200 μl of corn oil; or corn oil, 200 μl as control. 
Amounts  of  infused  total  T3s  were  2.00  and  1.99  mg  per  mouse  in  TRF  and  TRF/CD, 
respectively. Similarly, amounts of infused γ-T3 were 1.81 and 1.74 mg per mouse in TRF 
and  TRF/CD,  respectively.  The  level  of  -T3  in  tumors  was  determined  by  HPLC  as Functional Foods in Health and Disease 2011, 1(12):508-515                                                   Page 511 of 515 
 
 
described previously [15].    Total RNA was isolated using QIAshredder (Qiagen, Valencia, 
CA, USA) and the RNeasy Mini kit (Qiagen), according to the manufacturer's instructions. 
cDNA  was  synthesized.  Real-time  PCR  was  performed  by  using  an  ABI  Prism  7000 
Sequence  Detection  System  (Applied  Biosystems  Japan  Ltd.  Tokyo,  Japan)  and  SYBR 
Premix Ex Taq (TaKaRa Bio Inc., Shiga, Japan), according to the manufacturer’s instructions. 
The  primers  were  as  follows:  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH), 
accession  number  (BC023632),  sense  (nucleotides  737–756),  antisense  (nucleotides 
916–897); vascular endothelial growth factor (VEGF), accession number (NM_001025368), 
sense (nucleotides 1163–1182), antisense (nucleotides 1370–1390). Data is expressed as the 
mean±SD and analyzed by one-way ANOVA followed by Dunnett's t-test or Student's t-test 
only. P<0.05 was considered as showing a significant difference between means. 
 
RESULTS: 
We investigated the effect of -T3 inclusion with -CD on tumor development. Eight days 
after the inoculation of MSTO-211H cells in the subcutaneous tissue in the back of mice, a 
tumor  was  observed  in  each  group  (data  not  shown).  The  growth  of  the  tumor  was 
significantly suppressed in both TRF and TRF/CD groups compared with -CD group (Figure 
1). In addition, TRF/CD tended to exert a stronger anti-mesothelioma effect than TRF in the 
last stage, although there was no statistical difference.-T3 was detected in tumors from TRF 
and TRF/CD but not CD, in particular, the increase in -T3 level in the tumors was observed 
in TRF/CD group, although the difference was not significant (Figure 2).    Also, -T3 level 
in  plasma  from  each  group  showed  the  same  tendency  (data  not  shown).    Furthermore, 
TRF/CD and TRF treatment in tumor tissues significantly reduced mRNA level of VEGF 
(the major molecule necessary for angiogenesis) compared with -CD treatment (Figure 3). 
These results indicate that the inclusion with -CD is effective to enhance anti-mesothelioma 
effect which T3 has. 
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Figure 1. Effect of TRF and TRF/CD on the development of MSTO-211H tumors in nude 
mice.  Tumor  weight  was  measured  on  day  33  after  inoculation.  Each 
value  is  the  mean  of  three  determinants;  vertical  lines  indicate  SD.  *P<0.05 
compared to CD treatment. 
 
 
 
 
 
 
 
Figure 2. The accumulation of T3 in tumor tissues in mice treated with TRF and TRF/CD. 
Each  value  is  the  mean  of  three  determinants; vertical lines indicate SD. ND, not 
detected. 
 
Figure 3. Effects of TRF and TRF/CD treatment on the expression of VEGF in MSTO-211H 
tumors in nude mice. VEGF mRNA level was determined by RT-realtime PCR as described 
above. Each  value  is  the  mean  of  three  determinants; vertical lines indicate SD. 
*P<0.05 compared to CD treatment. 
 
DISCUSSION:   
In our previous study [16], we compared the bioavailability of  -T3 when given as a TRF 
inclusion complex with CD with that administered as a free form dissolved in corn oil. The 
Cmax and AUC values for plasma -T3 levels were markedly greater in mice administered 
TRF/CD orally than those given TRF alone. Moreover, TRF/CD-administered mice tended to 
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TRF alone. Form these results we concluded that these effects could be attributed, at least in 
part, to the elevated level of plasma -T3 level. Similarly, our present study indicated that 
TRF/CD  treatment  reinforced  anti-mesothelioma  effect  in  TRF  treatment  and  that  the 
reinforcement was associated with -T3 level in tumors and plasma. The present observation 
completely  supports  a  notion  that  the  inclusion  system  with  -CD  improves  the 
bioavailability of -T3, and that the improvement leads to enhancement of -T3 potential as 
an anti-mesothelioma agent. Thus, TRF/CD may be a promising procedure to utilize -T3 in 
complementary medicine against mesothelioma.   
With  respect  to  anti-cancer  mechanism  of  -T3,  several  types  of  targets  have  been 
reported  [9].  Of  the  determined  target  molecules,  c-Src  is  one  of  the  promising  target 
molecules  in  mesothelioma  [17].  The  expression  of  activated  c-Src  correlates  with 
advanced-stage and metastasis of mesothelioma [18]. It suggests the involvement of c-Src in 
driving  oncogenesis.  Furthermore,  inhibition  of  Src  expression  and  activation  in 
mesothelioma leads to apoptosis, cell cycle arrest, and suppression of invasion [19].    It has 
been  reported  that  T3  inhibited  c-Src  kinase  activity  or  regulated  one  or  more  events 
upstream of c-Src kinase activation in brain tissues [20]. Additionally, we observed that the 
expression of VEGF, a main molecule located in the downstream of c-Src signaling [21], was 
significantly suppressed by TRF and TRF/CD treatment. This observation strongly supports a 
hypothesis  that  the  inactivation  of  c-Src  and  its  related  signaling  closely  relate  to 
-T3-dependent  negative  growth  control  of  mesothelioma  cells  in  vivo.  Also,  we  can 
speculate  which  molecule  in  c-Src  signaling  contributes  to  the  suppression  of  VEGF 
expression in TRF and TRF/CD-treated mice, based on the following reports. (1) A signal 
transducer  and  activator  of  transcription  3  (Stat3)  is  determined  as  a  major  positive 
transcription factor for VEGF [22]; (2) the inhibition of c-Src leads to the inactivation of 
Stat3 as a transcription factor [22]; (3) consecutive activation of Stat3 has been observed in 
human mesothelioma cells [23]; (4) a specific inhibitor towards Stat3 effectively has negative 
growth control against mesothelioma cells [18]. These reports suggest that Stat3 is a main 
molecule in c-Src signaling to be necessary for anti-mesothelioma effect of -T3. Overall, it 
seems to be possible that c-Src/Stat3 signaling contribute to -T3-dependent negative growth 
control of mesothelioma cells in vivo. 
 
CONCLUSION: 
-T3 inclusion complex with CD is a promising procedure to improve human mesothelioma 
treatment. Functional Foods in Health and Disease 2011, 1(12):508-515                                                   Page 514 of 515 
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